A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach.

Q1 Computer Science
Digital Biomarkers Pub Date : 2020-11-26 eCollection Date: 2020-01-01 DOI:10.1159/000512513
Lynn Rochester, Claudia Mazzà, Arne Mueller, Brian Caulfield, Marie McCarthy, Clemens Becker, Ram Miller, Paolo Piraino, Marco Viceconti, Wilhelmus P Dartee, Judith Garcia-Aymerich, Aida A Aydemir, Beatrix Vereijken, Valdo Arnera, Nadir Ammour, Michael Jackson, Tilo Hache, Ronenn Roubenoff
{"title":"A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach.","authors":"Lynn Rochester,&nbsp;Claudia Mazzà,&nbsp;Arne Mueller,&nbsp;Brian Caulfield,&nbsp;Marie McCarthy,&nbsp;Clemens Becker,&nbsp;Ram Miller,&nbsp;Paolo Piraino,&nbsp;Marco Viceconti,&nbsp;Wilhelmus P Dartee,&nbsp;Judith Garcia-Aymerich,&nbsp;Aida A Aydemir,&nbsp;Beatrix Vereijken,&nbsp;Valdo Arnera,&nbsp;Nadir Ammour,&nbsp;Michael Jackson,&nbsp;Tilo Hache,&nbsp;Ronenn Roubenoff","doi":"10.1159/000512513","DOIUrl":null,"url":null,"abstract":"<p><p>Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care.</p>","PeriodicalId":11242,"journal":{"name":"Digital Biomarkers","volume":"4 Suppl 1","pages":"13-27"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000512513","citationCount":"53","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digital Biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000512513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Computer Science","Score":null,"Total":0}
引用次数: 53

Abstract

Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care.

数字化移动成果的开发、验证和批准路线图:Mobilise-D方法。
卫生保健必须迅速适应COVID-19,这反过来又突出了对便利远程就诊和监测工具的迫切需求。包括穿戴式设备在内的数字卫生技术提供了一种解决方案,使用数字结果来测量和监测疾病状况,并提供对患者和卫生保健专业人员都有意义的结果。对身体移动性的远程监控就是一个很好的例子,因为移动性是可以进行数字化和远程评估的最先进的模式之一。丧失行动能力也是许多健康状况的一个重要特征,提供了健康状况的读数以及干预的目标。现实世界中,持续的移动数字测量(数字移动结果或dmo)为对医疗保健状况的新见解提供了机会,补充了现有的移动测量。接受和批准的dmo尚未广泛使用。人们普遍认识到,需要大规模的协作努力来解决采用的关键步骤。Mobilise-D就是一个例子。它是一个由来自学术界和工业界的34个机构组成的多学科联盟,由欧洲创新药物倡议联合事业资助。动员- d的成员正在合作解决在临床试验和最终卫生保健中采用DMOs的关键步骤。为了实现这一目标,该联盟制定了路线图,为帕金森病、多发性硬化症、慢性阻塞性肺疾病和股骨近端骨折康复的DMOs的开发、验证和批准提供信息。在这里,我们旨在描述拟议的方法,并提供Mobilise-D联盟正在进行和计划中的工作的高层视图。最终,Mobilise-D旨在通过提供与设备无关的软件、标准和强大的验证来刺激dmo的广泛采用,从而将数字结果从概念带到临床试验和医疗保健中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Digital Biomarkers
Digital Biomarkers Medicine-Medicine (miscellaneous)
CiteScore
10.60
自引率
0.00%
发文量
12
审稿时长
23 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信